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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The primary objective is to assess the role of iridotomy-compared with observation-in the prevention of visual field loss for individuals
who have primary angle closure or primary angle-closure glaucoma in at least one eye. We will also examine the role of iridotomy in
the prevention of elevated intraocular pressure (IOP) in individuals with narrow angles (primary angle-closure suspect) in at least one
eye.
B A C K G R O U N D
Introduction
Glaucoma characterizes a group of similar diseases defined by pro-
gressive damage to the optic nerve (optic neuropathy) that occurs
in a characteristic pattern with associated changes in appearance
and visual field (Foster 2002). High intraocular pressure (IOP) is
associated with glaucomatous optic nerve damage. IOP can ele-
vate when aqueous humor, a clear fluid that continuously flows in
and out of the anterior chamber to nourish the eye, does not drain
properly (Mapstone 1968; EGS 2014; AAO 2015). When im-
pairment of aqueous drainage occurs at the trabecular meshwork
by the iris, this is referred to as angle closure (Emanuel 2014).
Optic nerve damage resulting from angle closure commonly is
described as primary angle-closure glaucoma (PACG), while op-
tic nerve damage without the angle closure is known as primary
open-angle glaucoma (POAG). Both open-angle and angle-clo-
sure glaucoma also can be classified as secondary when the condi-
tion is traced to an identifiable concomitant cause such as an eye
injury, eye inflammation, or other eye illnesses (Law 2013). A fur-
ther manifestation of angle closure is an acute ’attack’ or crisis, in
which sudden blockage to the drainage is associated with very high
intraocular pressures and symptoms including headache, blurred
vision and a severe dull eye pain.
Currently, there is increasing interest in examining the efficacy
of interventions for preventing PACG (Yu 2015). These include
medical or surgical treatments that aim to equalize the pressures
across the anterior and posterior chambers of the eye by allowing
the iris to fall back, away from the trabecular meshwork, in an at-
tempt to open the angles and lower IOP. Two common techniques
used to accomplish this objective are iridectomy-which involves
surgical removal of parts of the iris-and iridotomy-which involves
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the use of a laser to create a hole in the iris. Early studies exam-
ining angle-closure disease in the 1950s documented that when
the contralateral eye of a patient with angle-closure was given no
treatment or pilocarpine (once or twice daily), there was a 50%
chance over a period of 25 year sthat the patient would develop
acute attacks or a sudden rise in IOP (Lowe 1962; Lowe 1966).
Conversely, only 1 out of 54 patients treated with surgical iridec-
tomy during this same period of time developed an acute attack in
the untreated contralateral eye (Ang 2000; Edwards 1982; Snow
1977). Iridotomy is a less invasive and more common procedure
than iridectomy (Ramulu 2007). While both achieve the same
purpose, there are approximately 51 iridotomies for every iridec-
tomy performed.
For patients and their providers, a better understanding of an
intervention that addresses angle-closure glaucoma would assist in
deciding themost appropriate preventionmodality; for researchers
and decision makers, this information facilitates the design and
implementation of global screening programs and may be useful
for identifying persons at risk.
Epidemiology
Glaucoma is among the leading causes of blindness and, particu-
larly due to the irreversible nature of the disease, a pressing public
health challenge (Kingman 2004; Resnikoff 2004; Bourne 2013).
The World Health Organization characterizes glaucoma as one of
its priority eye diseases, and researchers have approximated that
about five million people today are blind as a consequence of glau-
coma (Osborne 2003; Quigley 2006). A recent systematic review
found a global prevalence of glaucoma in the 40 to 80 years age
group of 3.54%, and estimated that prevalence will reach 76 mil-
lion by 2020 and 111.8 million by 2040 (Tham 2014). The preva-
lence of angle-closure glaucoma in particular is estimated to rise
to 21 million by 2020 (Quigley 2006).
PACG is less common among Caucasians, with pooled prevalence
of PACG for people aged 40 years or older from European ances-
try estimated to be 0.4% (Day 2012). PACG, however, is more
prevalent in Asians of Mongolian descent (Bonomi 2002; Tham
2014). Among the 64.26 million people with glaucoma aged 40
to 80 years, 20.17 million are estimated to have PACG in 2013;
among this sub-population, 14.47 million are estimated to be liv-
ing in Asia (Quigley 2006; Tham 2014). For example, in China,
91% of the 1.7 million cases of bilateral blindness are attributable
to PACG (Foster 2001; Ng 2012). The prevalence also appears
to be greater among older women, compared with their male and
younger counterparts in all ethnic populations (Bonomi 2002;
Day 2012). There is substantial variation in the data on the inci-
dence rates for PACG, ranging from 4 per 100,000 person-years
to 58.7 per 100,000 person-years (Erie 1997; Lai 2001; Ivanisevic
2002).
Description of the condition
The consensus view regarding the mechanism of elevation in IOP
in angle-closure glaucoma has identified pupillary block as the
major mechanism, which limits the flow of aqueous fluid from
the posterior to the anterior chamber of the eye (Friedman 2001;
Foster 2002; AAO 2015). The pressure differential created by
the build-up of fluid causes the iris to bulge forward and come
into iridotrabecular contact (ITC) with the trabecular meshwork
and peripheral cornea (Mapstone 1968; AAO 2015). This contact
causes a rise in the IOP by reducing the outflow of aqueous fluids.
Another important mechanism that is often associated with the
development of angle closure is a plateau iris configuration. A
plateau iris is the result of narrowing of the anterior chamber,
pushing peripheral parts of the iris forward by displacement of
the ciliary body anteriorly, leading to continuation of ITC (AAO
2015).
For this review, we follow a recently proposed classification of an-
gle-closure glaucoma (Foster 2000; Aung 2001; Foster 2002; Ng
2012; AAO 2015). This definition rests on the idea of describing
an ’occludable’ angle, using terms such as ’narrow’ to specify the
anatomical predisposition to angle closure, further qualified by
degrees of ITC and whether or not the patient has peripheral an-
terior synechiae (PAS). The drainage angle is easily and painlessly
assessable through a gonioscopy during an eye exam.
• Primary angle-closure suspects (PACS) are patients
described as having narrow angles, where there is appositional or
synechial contact 180 degrees or more, as observed on
gonioscopy, between the peripheral iris and the posterior
trabecular meshwork; however, there is no evidence of
permanent aqueous outflow obstruction or damage to the angle.
In other words, there is neither elevated IOP nor PAS.
Accordingly, there are also no signs of elevated IOP or
glaucomatous optic disc neuropathy.
• Patients with primary angle-closure (PAC) are those
showing signs of chronic angle damage beyond narrow angles
with iridotrabecular contact in three or more quadrants at least
180 degrees, therefore obstruction by the peripheral iris has
occurred and there is elevated IOP and/or PAS but no signs of
glaucomatous optic disc neuropathy.
• Primary angle-closure glaucoma (PACG) patients are those
with 180 degrees of angle or greater in which the posterior
(usually pigmented) and presumed functional trabecular
meshwork is not visible and there is the presence of
glaucomatous optic nerve damage in addition to elevated eye
pressure and/or PAS as described for PAC.
The American Academy of Ophthalmology in its 2015 Preferred
Practice Patterns for Primary Angle Closure summarizes clinical
findings defining patients seen with angle-closure disease (AAO
2015) (Table 1). This classification for the progression from PACS
to PAC to PACG suggests potential for preventing the conse-
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quences of narrow angles and angle closure through early detec-
tion and treatment. More traditional definitions of PACG and
angle-closure disease were based on whether nor not symptoms
occur acutely or chronically (e.g., having acute angle-closure crisis
or AACC). For this review, we are treating acute angle-crisis or
attacks as separate clinical conditions, despite similar mechanisms,
and will not consider AACC for this review.
Description of the intervention
Iridotomy is a laser-assisted surgical procedure aimed at creating
an opening in the peripheral part of the iris and is conducted as an
outpatient procedure involving the use of a laser (e.g., neodymium-
doped yttrium aluminium garnet or Nd:YAG laser, argon laser)
and slit lamp biomicroscope (AAO 2015; Nolan 2000).
While iridotomy is also the standard of care for treating PAC and
PACG (AAO 2015), there are some limitations and risks to using
this procedure. By disrupting the natural flow of aqueous fluids in
the eye, which may in turn result in significant increase in contact
between the lens and the iris, there is a theoretical risk of more
rapid development of cataracts (Caronia 1996). Other potential
risks include rare occurrence of corneal endothelial damage local-
ized to the surgery site, stray light symptoms, and the develop-
ment of posterior synechiae (Pollack 1981; Quigley 1981; Robin
1984). Posterior synechiae potentially can limit vision in dimly-
lit environments and complicate cataract surgery or pan retinal
photocoagulation.
How the intervention might work
Iridotomy removes pupillary block by making an opening in the
peripheral iris; this hole-created through the use of a laser-provides
for free circulation of aqueous from posterior to anterior chambers
even if the pupil becomes blocked (Fleck 1997; Friedman 2001;
Ng 2012). This opening prevents IOP from rising further, which
in theory should minimize subsequent optic nerve damage and
progression of visual field loss.
Why it is important to do this review
Understanding the preventative effects of laser iridotomy in pri-
mary angle-closure suspects and patients with iridotrabecular con-
tact are high-priority clinical questions that reflect the Ameri-
can Academy of Ophthalmology’s Preferred Practice Patterns rec-
ommendations for management of primary angle-closure (AAO
2015). Epidemiologists have pointed out this topic area as an ev-
idence gap for the management of PAC (Yu 2015).
While there is some evidence that a prophylactic iridotomy sig-
nificantly reduces the risk of angle closure (i.e., PAC or PACG)
in the contralateral eye of an individual who has previously been
diagnosed with angle closure or PACG, there is much confusion
regarding the need for a prophylactic iridotomy in eyes of patients
with asymptomatic narrow angles noted through gonioscopy, i.e.,
PAC suspects (Snow 1977; Edwards 1982; Ang 2000). Similarly,
some research findings suggest that iridotomy may be insufficient
for long-term control of IOP (See 2011). Lastly, while compli-
cations of laser-assisted iridotomy seem minor relative to the risk
and burden of angle closure, they are of significant concern for pa-
tients considering these procedures, particularly in East Asia and
India (Dandona 2000; Foster 2000; Ramakrishnan 2003). For
instance, if iridotomy hastens the progression of cataracts signif-
icantly, these procedures may cause more cataract-related blind-
ness with widespread screening and usage of iridotomy treatment,
especially in an environment such as a low- and middle-income
country where cataract services are not universally available.
O B J E C T I V E S
The primary objective is to assess the role of iridotomy-compared
with observation-in the prevention of visual field loss for indi-
viduals who have primary angle closure or primary angle-closure
glaucoma in at least one eye. We will also examine the role of iri-
dotomy in the prevention of elevated intraocular pressure (IOP)
in individuals with narrow angles (primary angle-closure suspect)
in at least one eye.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomized controlled trials (RCTs). Given that
there may be few RCTs on this intervention, we also will include
quasi-randomized trials and will address potential selection bias
in the analysis and discussion. We define quasi-randomized tri-
als as studies that employed a method of allocating patients to a
treatment arm that is not strictly random (e.g., by date of birth,
hospital record number, in alternation, etc).
Types of participants
We will include studies of participants with gonioscopically-nar-
row angles-i.e. primary angle-closure suspects (PACS), those with
primary angle closure (PAC), or those with primary angle-closure
glaucoma in one or both eyes. We will not restrict by age, gender
or ethnicity.
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Types of interventions
We will include only trials that compared iridotomy versus ob-
servation (i.e., no surgical treatment) or sham treatment with or
without IOP-lowering medication.
Types of outcome measures
Primary outcomes
• Progressive visual field loss at one year, defined as the
proportion of participants with evidence of progression of visual
field loss, measured using a validated method, at one year of
follow up. These methods include, but are not limited to
automated Humphrey Field Analyzer, Heidelberg Edge
Perimeter, or Oculus. We also will consider other time points
during follow-up as reported in the included studies. We will
only assess this outcome for studies involving patients with PAC
or PACG.
Secondary outcomes
The secondary outcomes for comparison of interventions include
the following.
1. Mean change in IOP from baseline to one year, measured
by any method of applanation tonometry, e.g. Goldmann or
Perkins.
2. Gonioscopic findings in the participant, including angle
width and presence of PAS, as reported by the investigators.
3. Need for additional surgery, as defined by the proportion of
participants who received additional surgery to control IOP
within one year after iridotomy.
4. Number of medications used to control IOP at one year.
5. Mean change in best corrected visual acuity (BCVA) as
measured by logMAR from baseline to one year after iridotomy.
6. Quality of life data will be tabulated as documented.
To improve comparability and consistency, we have adapted some
of the above outcomes from previous Cochrane reviews (Friedman
2006; Zhang 2015).
Adverse events
1. Adverse effects, including IOP spikes, persistent IOP
elevation, hyphema and other adverse effects will be reported as
documented.
Search methods for identification of studies
Electronic searches
We will search CENTRAL (which contains the Cochrane Eyes
and Vision Trials Register) (latest issue), Ovid MEDLINE, Ovid
MEDLINE In-Process and Other Non-Indexed Citations, Ovid
MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to
present), EMBASE (January 1980 to present), PubMed (January
1948 to present), Latin American and Caribbean Health Sci-
ences Literature Database (LILACS) (1982 to present), Clinical-
Trials.gov (www.clinicaltrials.gov), and the World Health Orga-
nization (WHO) International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en).Wewill not use any date
or language restrictions in the electronic searches.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1),MEDLINE (Appendix 2), EMBASE (Appendix 3),
PubMed (Appendix 4), LILACS (Appendix 5), ClinicalTrials.gov
(Appendix 6) and the ICTRP (Appendix 7).
Searching other resources
We intend to search the references of included studies for informa-
tion about further trials. We do not intend to handsearch journals
and conference proceedings.
Data collection and analysis
Selection of studies
Two review authors independently will screen titles and abstracts
of all records identified in the searches.We will classify each record
as either ’relevant’ or ’not relevant’ for full-text review. The full-
text copies of all studies that we identify for full-text review will
be assessed by two review authors independently to determine if
they meet the inclusion criteria (’Yes’ or ’No’). We will contact the
trial authors to clarify any details necessary to make a complete
assessment of the relevance or design of the study. We will docu-
ment reasons for exclusion for each study assessed as not eligible
after review of the full-text reports. We will resolve discrepancies
between review authors by discussion at each stage of the selection
process.
Data extraction and management
Two review authors independently will extract data for the pri-
mary and secondary outcomes using a web-based electronic data
collection form (Appendix 8). We will extract information on the
study design (e.g., study setting, countries where recruitment took
place, sample size, study duration and follow-up time, study de-
sign, analysis choice, sources of funding, and potential conflicts
of interests), characteristics of the participants (e.g., inclusion/ex-
clusion criteria, underlying disease conditions, and medical his-
tory, including visual acuity and other vision-related characteris-
tics), interventions and comparators (e.g., type of laser, duration
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and timing), and outcomes (e.g., domain, specific measurement,
specific metric, method of aggregation, and the time frame).
The two authors will then compare the extracted data and resolve
discrepancies by discussion, and when necessary, through consul-
tation with the third author. One review author will complete data
entry into RevMan 5.3 (RevMan 2014) and a second author will
verify the data entered.
Assessment of risk of bias in included studies
Two review authors independently will assess the risk of bias in
included studies following the guidance enumerated in Chapter
8 of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). Specific items to consider will include random
sequence generation and allocation concealment (selection bias),
masking of participants and study personnel (performance bias),
masking of outcome assessors (detection bias), missing data and
intention-to-treat analysis (attrition bias), selective outcome re-
porting (reporting bias) and other potential sources of bias. We
will assign each item as having ’low risk’, ’high risk’, or, if the in-
formation provided is insufficient to make an assessment, ’unclear
risk’ . We will document reasons for those assessments.
Any discrepancy will be resolved through discussion, and when
necessary, through consultation with a third author or by contact-
ing the study investigators as appropriate. In the event of the latter,
if the study investigator does not respond within two weeks, the
review authors will use the information available in published re-
ports to judge risk of bias. We will present the overall assessments
as the ’Risk of bias summary’ figure and graph (Higgins 2011).
Measures of treatment effect
We will report risk ratios with 95% confidence intervals (CIs)
for any dichotomous outcomes and mean differences in change
from baseline with 95% CIs for continuous outcomes (i.e., mean
change in IOP, progressive field loss, number of medications used,
and mean change in BCVA).Wewill conduct separate analyses for
outcomes in the eyes of participants with angle-closure glaucoma,
for outcomes in the eyes of participants with angle closure, and for
outcomes in the eyes with only narrow angles but no obstructions
(i.e. PACS). If any trials on eyes with narrow angles compared eyes
within individuals (e.g., one eye was randomized to the treatment
while the other was randomized to observation), then we will note
whether or not the study investigators included statistical methods
accounting for the correlation between eyes belonging to the same
individual.
Unit of analysis issues
Our unit of analysis is one study eye per individual participant,
therefore accounting for non-independence of eyes is not neces-
sary.
We also will consider studies that included two eyes per partici-
pant. In this situation, if both eyes of the same participant received
the same treatment assignment and if both eyes were treated as a
single unit, then our unit of analysis is the participant. However,
if both eyes of participants either received different treatment as-
signments or were treated as two distinct units, thenwe will review
the publication to see if the study investigators properly accounted
for the non-independence of eyes. If they did not account for this
potential correlation, then we will seek the expertise of a statistical
consultant and account for this in the discussion of the review.
Dealing with missing data
We will address any missing study data for the outcomes of inter-
est or any unclear information by writing to the authors. Should
there be no response within two weeks, we will analyze the data
using the best available information. We also will consider multi-
ple imputation or other imputation approaches for missing data.
In the event that the quality of the available data prevents any
meaningful analysis, we will omit the study from the analyses and
note this decision in the discussion.
Assessment of heterogeneity
We will assess clinical and methodological heterogeneity by exam-
ining participant characteristics, iridotomy procedures, and out-
comes by carefully reviewing the study publication and taking into
consideration potential risk of bias. This heterogeneity also will
manifest as statistical heterogeneity which we will examine by as-
sessing forest plots and examining the I2 value and its confidence
interval (Deeks 2011). An I2 value that is greater than 70% will
suggest substantial statistical heterogeneity, therefore a meta-anal-
ysis might not be appropriate; however, we will give consideration
to the consistency of the effect estimates. For example, if we find
that all effect estimates are in the same direction, we may report
a meta-analysis even though there may be substantial statistical
heterogeneity.
Assessment of reporting biases
We will assess publication bias through constructing a funnel plot
when there are 10 or more trials included in our review. We will
assess for selective outcome reporting as part of the ’Risk of bias’
assessment.
Data synthesis
We will follow Chapter 9 of the Cochrane Handbook for Systematic
Reviews of Interventions for data analysis (Deeks 2011). In the ab-
sence of substantial clinical and methodological heterogeneity, we
will use a random-effects model to compute a quantitative syn-
thesis. When the number of studies is less than 3 and there is no
evidence of substantial statistical heterogeneity, we may consider
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fixed-effect meta-analysis. We also will provide a descriptive, qual-
itative synthesis of studies and their results.
Subgroup analysis and investigation of heterogeneity
We will consider the following subgroups: a) with or without use
of IOP-lowering medications, and b) by ethnic/racial groups.
Sensitivity analysis
We will conduct two sensitivity analyses to determine the effect of
excluding studies at high risk of bias for incomplete outcome data
and the effect of excluding studies that were quasi-randomized
trials. If appropriate, we also will conduct additional sensitivity
analyses to determine the impact of any post-hoc decisions made
during the review process.
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A D D I T I O N A L T A B L E S
Table 1. AAO summary of clinical findings defining angle-closure diseases
Primary angle-closure suspect
(PACS)
Primary angle closure (PAC) Primary angle-closure glau-
coma (PACG)







Optic nerve damage X
ITC: iridotrabecular contact
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Glaucoma, Angle-Closure] explode all trees
#2 (angle* near/3 closure*)
#3 (angle* near/3 close*)
#4 (Uncompensat* near/2 glaucoma*)
#5 (Narrow* near/2 angle*)
#6 (occlude* near/3 angle*)
#7 Acute glaucoma*
#8 (APAC or AACG or PACG or PACS)
#9 pupillary block glaucoma*
#10 {or #1-#9}
#11 MeSH descriptor: [Laser Therapy] explode all trees
#12 MeSH descriptor: [Lasers] explode all trees
#13 Laser*
#14 (iridotom* or LPI)
#15 {or #11-#14}
#16 #10 AND #15
Appendix 2. MEDLINE (Ovid) search strategy
1. exp Glaucoma, Angle-Closure/
2. (angle* adj3 closure*).tw.
3. (angle* adj3 close*).tw.
4. (Uncompensat* adj2 glaucoma*).tw.
5. (Narrow* adj2 angle*).tw.
6. (occlude* adj3 angle*).tw.
7. Acute glaucoma*.tw.
8. (APAC or AACG or PACG or PACS).tw.
9. pupillary block glaucoma.tw.
10. or/1-9
11. exp Laser Therapy/
12. exp Lasers/
13. Laser*.tw.
14. (iridotom* or LPI).tw.
15. or/11-14
16. 10 and 15
Appendix 3. EMBASE.com search strategy
#1 ’closed angle glaucoma’/exp
#2 (angle* NEAR/3 closure*):ab,ti
#3 (angle* NEAR/3 close*):ab,ti
#4 (uncompensat* NEAR/2 glaucoma*):ab,ti
#5 (narrow* NEAR/2 angle*):ab,ti
#6 (occlude* NEAR/3 angle*):ab,ti
#7 (acute NEAR/1 glaucoma*):ab,ti
#8 apac:ab,ti OR aacg:ab,ti OR pacg:ab,ti OR pacs:ab,ti
#9 (’pupillary block’ NEAR/2 glaucoma):ab,ti
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#10 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9




#15 iridotom*:ab,ti OR lpi:ab,ti
#16 #11 OR #12 OR #13 OR #14 OR #15
#17 #10 AND #16
Appendix 4. LILACS search strategy
(“Glaucoma de Ángulo Cerrado” OR “Glaucoma de ngulo Fechado” OR MH:C11.525.381.056$ OR (angle$ AND (closure$ OR
close$ OR narrow$ OR occlude$)) OR (Uncompensat$ glaucoma$) OR (Acute glaucoma$) OR (pupillary block glaucoma$) OR
APAC OR AACG OR PACG OR PACS) AND (Laser$ OR iridotom$ or LPI OR MH:E02.594$ OR MH:E04.014.520$ OR MH:
E07.632.490$ OR MH:E07.710.520$ OR MH:SP4.011.087.698.384.075.166.027$ OR MH:VS2.006.002.009$)
Appendix 5. PubMed search strategy
1. (angle*[tw] AND closure*[tw]) NOTMedline[sb]
2. (angle*[tw] AND close*[tw]) NOTMedline[sb]
3. (Uncompensat*[tw] AND glaucoma*[tw]) NOTMedline[sb]
4. (Narrow*[tw] AND angle*[tw]) NOTMedline[sb]
5. (occlude*[tw] AND angle*[tw]) NOTMedline[sb]
6. Acute glaucoma*[tw] NOTMedline[sb]
7. (APAC[tw] or AACG[tw] or PACG[tw] or PACS[tw]) NOT Medline[sb]
8. pupillary block glaucoma[tw] NOTMedline[sb]
9. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
10. Laser*[tw] NOTMedline[sb]
11. (iridotom*[tw] OR LPI[tw]) NOTMedline[sb]
12. #10 OR #11
13. #9 AND #12
Appendix 6. ClinicalTrials.gov search strategy
Angle closure glaucoma OR Acute glaucoma OR pupillary block glaucoma
Appendix 7. ICTRP search strategy
Angle closure glaucoma OR Acute glaucoma OR pupillary block glaucoma OR narrow-angle glaucoma OR uncompensated glaucoma
OR uncompensative glaucoma
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Appendix 8. Data on study characteristics
Mandatory items Optional items
Methods
Study design · Parallel group RCT i.e. people random-
ized to treatment
· Within-person RCT i.e. eyes randomized
to treatment





Losses to follow up
Number randomized/analyzed
Howweremissing data handled? e.g., avail-
able case analysis, imputation methods
Reported power calculation (Y/N), if yes,
sample size and power
Unusual study design/issues
Eyes or
Unit of randomization/ unit of analysis
· One eye included in study, specify how
eye selected
· Two eyes included in study, both
eyes received same treatment, briefly spec-
ify how analyzed(best/worst/average/both and
adjusted for within person correlation/both
and not adjusted for within person correla-
tion) and specify if mixture one eye and two
eye
· Two eyes included in study, eyes re-
ceived different treatments, specify if cor-




Equivalence of baseline characteristics (Y/
N)
Total number of participants This information should be collected for total
study population recruited into the study. If
these data are only reported for the people who
were followed up only, please indicate.
Number (%) of men and women






See MECIR 65 and 70
· Number of people randomized to this
group
· Drug (or intervention) name
· Dose
· Frequency
· Route of administration
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(Continued)
Outcomes




Adverse events reported (Y/N)
Length of follow up and intervals at which
outcomes assessed
Planned/actual length of follow up
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